Dr. Erin Hofstatter gives some "red flags" that indicate a patient or family member should consider genetic counseling and testing.
Erin Hofstatter, MD, from Smilow Cancer Hospital and Yale Medical School, gives some indications that should prompt a patient or family member to go for genetic counseling and testing.
Hofstatter goes over the “classic red flags” that can indicate hereditary cancer risk and a need for genetic counseling and testing, including patients or family members diagnosed at a younger age or if the family history has a clustering of breast and ovarian cancer, or breast, ovarian and pancreatic cancers.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki in HER2+ Solid Tumors
April 5th 2024The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.